3 FDA decisions that could be delayed if the U.S. defaults on its debt

If federal lawmakers don’t vote to raise the debt limit by early June, these FDA actions could be impacted.

By Karissa Waddick • May 30, 2023

CVS is exiting clinical trials. Does this spell trouble for retail-based research?

Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.

By Kelly Bilodeau • May 30, 2023

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

The ‘superpowers’ pharma leaders should cultivate

Executives honored by the Healthcare Businesswomen’s Association share the key traits that help them drive results.

By Taren Grom • May 26, 2023

From FTC to SCOTUS, Amgen’s woes are potential ‘game changers’ for the industry

The two institutional battles offer a glimpse into the tension between pharma innovation and regulation that could reverberate across the industry.

By Michael Gibney • May 25, 2023

Strangers in a strange land: 8 unlikely companies making plays in pharma

How these consumer and service companies are tapping into major trends in the biopharma industry.

By Karissa Waddick • May 22, 2023

The problem solver: How Benjamin Moutier is pushing boundaries and striving for solutions in haematology

In Benjamin Moutier’s new role in haematology, he says he will focus on leading transformational changes that will pave the way to developing therapies and improving outcomes across a broad range of haematological diseases. 

May 22, 2023

What pharma can teach biotech about the life cycle management of a drug

Global product teams are common in pharma but have yet to gain traction in biotech. Here's why this model can work.

By Dr. Stephen Dale and Kathleen Ford • May 18, 2023

A day in the life of a pharma exec: Lyndra’s Patricia Hurter

How the CEO starts each day with a ride on one of her horses, reduces daily meetings and uses her network to get through crises like the SVB Bank collapse.

By Meagan Parrish • May 17, 2023

Major regulatory changes are coming to pharma in the EU — and industry’s weighing in

The European Union published a long-awaited proposal that could bring sweeping changes to its pharma sector last month, but the legislative fight has only just begun.

By Karissa Waddick • May 16, 2023

Years into the pandemic, only a handful of clinical trials are targeting long COVID — here’s one of them

Scientists at Stanford are testing Pfizer’s Paxlovid on long COVID symptoms and their efforts could provide clues for other conditions.  

By Kelly Bilodeau • May 15, 2023

How pharma’s rocky real estate market has changed — for better and worse

Whether you’re looking to build a new site or expand lab space, here are the biggest trends impacting life sciences real estate.

By Karissa Waddick • May 11, 2023

Woman of the Week: Reneo Pharmaceuticals’ Ashley Hall

After ushering a blockbuster to market, the chief development officer is channeling her experience into the rare disease space.

By Taren Grom • May 10, 2023

AbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’

With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.

By Taren Grom • May 10, 2023

Led by the Pfizer-Seagen deal, ADCs are starting to ‘take center stage’

Antibody-drug conjugates got a major boost with the megamerger of Pfizer and Seagen, and experts believe they will continue to be an important catalyst in biopharma.

By Michael Gibney • May 9, 2023

Insulin prices have dropped — will Civica still be a disrupter in the field?

The nonprofit generics maker still sees a need for low-cost insulin despite recent moves by major drugmakers to slash the prices of their popular products. 

By Karissa Waddick • May 8, 2023

3 key FDA approval trends this year

Although approvals are off to a slow start in oncology, the agency has been living in the fast lane for neurological disorders and more.

By Kelly Bilodeau • May 8, 2023

A biopharma CEO opens up about executive salaries — and why he wants to change the status quo

With leaders at the biggest biopharma companies bringing in millions, the CEO of Corvus Pharmaceuticals opted for a pay cut to pour more funds into science.

By Michael Gibney • May 4, 2023

Navigating workforce challenges amid a turbulent biopharma market

A number of biopharma companies slashed their workforces this year and as market anxieties persist, more challenges could be looming.

By Karissa Waddick • May 4, 2023

Woman of the Week: Jazz Pharmaceuticals’ Neena Patil

Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.

By Taren Grom • May 3, 2023

Taking your biotech global? Here’s how you can navigate cultural norms

What’s so different about doing pharma business in the U.K. versus Japan? One of Moderna’s top brass shares her tips for navigating choppy cultural waters.

By Alexandra Pecci • May 2, 2023

BMS’s CEO transition will be a major test for the pharma giant

Come November, Chris Boerner will take the top spot as the company approaches patent cliffs for three drugs in the next decade.

By Karissa Waddick • April 28, 2023

How biopharma dealmaking kicked back into action

Events over the last year, including Pfizer’s Seagen buy and AstraZeneca’s CinCor deal, have foreshadowed the comeback of biopharma M&A.

By Michael Gibney • April 27, 2023

Pharma’s immunology field is full of blockbusters, and it’s just getting started

From the "father" of the IL-23 pathway at Janssen to a big acquisition by Merck, the ultra-competitive immunology space is still growing with the pace of innovation.

By Michael Gibney • April 27, 2023

Roy Vagelos is retiring and leaving a legacy of leadership lessons

The longtime pharma leader is stepping down from his role as chair of Regeneron’s board in June after decades in drug development. 

By Karissa Waddick • April 25, 2023

Tuberculosis is the world’s deadliest infectious disease — and treatments remain underfunded

Tuberculosis control and funding lost 20 years of progress during the COVID-19 pandemic, but scientists and world health groups are still plugging away.

By Alexandra Pecci • April 24, 2023